#### Rosa Bacchetta

# List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/2685067/rosa-bacchetta-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10,580 104 51 102 h-index g-index citations papers 8.7 111 12,215 5.94 L-index avg, IF ext. citations ext. papers

#	Paper	IF	Citations
104	Co-Expression of FOXP3FL and FOXP3½ Isoforms Is Required for Optimal Treg-Like Cell Phenotypes and Suppressive Function. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 752394	8.4	O
103	Engineered type 1 regulatory T cells designed for clinical use kill primary pediatric acute myeloid leukemia cells. <i>Haematologica</i> , <b>2021</b> , 106, 2588-2597	6.6	4
102	Alloantigen-specific type 1 regulatory T cells suppress through CTLA-4 and PD-1 pathways and persist long-term in patients. <i>Science Translational Medicine</i> , <b>2021</b> , 13, eabf5264	17.5	2
101	BHLHE40 Regulates IL-10 and IFN- Production in T Cells but Does Not Interfere With Human Type 1 Regulatory T Cell Differentiation. <i>Frontiers in Immunology</i> , <b>2021</b> , 12, 683680	8.4	O
100	Thymic origins of autoimmunity-lessons from inborn errors of immunity. <i>Seminars in Immunopathology</i> , <b>2021</b> , 43, 65-83	12	2
99	Pre-clinical development and molecular characterization of an engineered type 1 regulatory T-cell product suitable for immunotherapy. <i>Cytotherapy</i> , <b>2021</b> , 23, 1017-1028	4.8	1
98	Human-engineered Treg-like cells suppress FOXP3-deficient T cells but preserve adaptive immune responses. <i>Clinical and Translational Immunology</i> , <b>2020</b> , 9, e1214	6.8	6
97	CRISPR-based gene editing enables gene repair in IPEX patient cells. Science Advances, 2020, 6, eaaz057	<b>1</b> 14.3	38
96	Hematopoietic Cell Transplantation in Patients With Primary Immune Regulatory Disorders (PIRD): A Primary Immune Deficiency Treatment Consortium (PIDTC) Survey. <i>Frontiers in Immunology</i> , <b>2020</b> , 11, 239	8.4	25
95	Human inborn errors of immunity: An expanding universe. Science Immunology, 2020, 5,	28	58
94	Treatment with rapamycin can restore regulatory T-cell function in IPEX patients. <i>Journal of Allergy and Clinical Immunology</i> , <b>2020</b> , 145, 1262-1271.e13	11.5	24
93	The autoimmune targets in IPEX are dominated by gut epithelial proteins. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 327-330.e8	11.5	6
92	Case Study: Mechanism for Increased Follicular Helper T Cell Development in Activated PI3K Delta Syndrome. <i>Frontiers in Immunology</i> , <b>2019</b> , 10, 753	8.4	12
91	Severe autoinflammation in 4 patients with C-terminal variants in cell division control protein 42 homolog (CDC42) successfully treated with IL-1 Inhibition. <i>Journal of Allergy and Clinical Immunology</i> , <b>2019</b> , 144, 1122-1125.e6	11.5	55
90	Long-term follow-up of IPEX syndrome patients after different therapeutic strategies: An international multicenter retrospective study. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 103	36-1-04	9 <sup>1</sup> 57
89	Role of human forkhead box P3 in early thymic maturation and peripheral T-cell homeostasis. Journal of Allergy and Clinical Immunology, <b>2018</b> , 142, 1909-1921.e9	11.5	12
88	From IPEX syndrome to FOXP3 mutation: a lesson on immune dysregulation. <i>Annals of the New York Academy of Sciences</i> , <b>2018</b> , 1417, 5-22	6.5	186

## (2015-2018)

87	Peanut-specific type 1 regulatory T cells induced in vitro from allergic subjects are functionally impaired. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 141, 202-213.e8	11.5	20
86	Epigenetic immune cell counting in human blood samples for immunodiagnostics. <i>Science Translational Medicine</i> , <b>2018</b> , 10,	17.5	35
85	Reprogramming human T cell function and specificity with non-viral genome targeting. <i>Nature</i> , <b>2018</b> , 559, 405-409	50.4	367
84	Neutralizing Anti-Cytokine Autoantibodies Against Interferon-lin Immunodysregulation Polyendocrinopathy Enteropathy X-Linked. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 544	8.4	19
83	APVO210: A Bispecific Anti-CD86-IL-10 Fusion Protein (ADAPTIR) to Induce Antigen-Specific T Regulatory Type 1 Cells. <i>Frontiers in Immunology</i> , <b>2018</b> , 9, 881	8.4	12
82	Identity and Diversity of Human Peripheral Th and T Regulatory Cells Defined by Single-Cell Mass Cytometry. <i>Journal of Immunology</i> , <b>2018</b> , 200, 336-346	5.3	51
81	The Biology of T Regulatory Type 1 Cells and Their Therapeutic Application in Immune-Mediated Diseases. <i>Immunity</i> , <b>2018</b> , 49, 1004-1019	32.3	123
80	Tregopathies: Monogenic diseases resulting in regulatory T-cell deficiency. <i>Journal of Allergy and Clinical Immunology</i> , <b>2018</b> , 142, 1679-1695	11.5	65
79	Type 1 Diabetes Mellitus in Monogenic Autoimmune Diseases. Frontiers in Diabetes, 2017, 78-90	0.6	2
78	Minimum Information about T Regulatory Cells: A Step toward Reproducibility and Standardization. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1844	8.4	34
77	Severe Toxoplasma gondii infection in a member of a NFKB2-deficient family with T and B cell dysfunction. <i>Clinical Immunology</i> , <b>2017</b> , 183, 273-277	9	10
76	Ectopic FOXP3 Expression Preserves Primitive Features Of Human Hematopoietic Stem Cells While Impairing Functional T Cell Differentiation. <i>Scientific Reports</i> , <b>2017</b> , 7, 15820	4.9	12
75	Forkhead-Box-P3 Gene Transfer in Human CD4 T Conventional Cells for the Generation of Stable and Efficient Regulatory T Cells, Suitable for Immune Modulatory Therapy. <i>Frontiers in Immunology</i> , <b>2017</b> , 8, 1282	8.4	18
74	Immunodysregulation, Polyendocrinopathy, and Enteropathy, X-Linked (IPEX) Syndrome <b>2016</b> , 444-450		
73	Congenital Immunodeficiency Diseases <b>2016</b> , 45-81		
7 <sup>2</sup>	Chemically modified guide RNAs enhance CRISPR-Cas genome editing in human primary cells.  Nature Biotechnology, 2015, 33, 985-989	44.5	626
71	Congenital diarrhoeal disorders: advances in this evolving web of inherited enteropathies. <i>Nature Reviews Gastroenterology and Hepatology</i> , <b>2015</b> , 12, 293-302	24.2	58
70	Hurdles in therapy with regulatory T cells. <i>Science Translational Medicine</i> , <b>2015</b> , 7, 304ps18	17.5	114

69	Fatal autoimmunity in mice reconstituted with human hematopoietic stem cells encoding defective FOXP3. <i>Blood</i> , <b>2015</b> , 125, 3886-95	2.2	26
68	Forkhead box P3: the peacekeeper of the immune system. <i>International Reviews of Immunology</i> , <b>2014</b> , 33, 129-45	4.6	30
67	Clinical features and follow-up in patients with 22q11.2 deletion syndrome. <i>Journal of Pediatrics</i> , <b>2014</b> , 164, 1475-80.e2	3.6	83
66	Regulatory T cells and their roles in immune dysregulation and allergy. <i>Immunologic Research</i> , <b>2014</b> , 58, 358-68	4.3	75
65	Gene/cell therapy approaches for Immune Dysregulation Polyendocrinopathy Enteropathy X-linked syndrome. <i>Current Gene Therapy</i> , <b>2014</b> , 14, 422-8	4.3	19
64	Immunological Outcome in Haploidentical-HSC Transplanted Patients Treated with IL-10-Anergized Donor T Cells. <i>Frontiers in Immunology</i> , <b>2014</b> , 5, 16	8.4	107
63	Tr1 cells and the counter-regulation of immunity: natural mechanisms and therapeutic applications. <i>Current Topics in Microbiology and Immunology</i> , <b>2014</b> , 380, 39-68	3.3	161
62	Intergenerational and intrafamilial phenotypic variability in 22q11.2 deletion syndrome subjects. <i>BMC Medical Genetics</i> , <b>2014</b> , 15, 1	2.1	28
61	Identification of STAT5A and STAT5B target genes in human T cells. <i>PLoS ONE</i> , <b>2014</b> , 9, e86790	3.7	49
60	Differentiating the roles of STAT5B and STAT5A in human CD4+ T cells. <i>Clinical Immunology</i> , <b>2013</b> , 148, 227-36	9	35
59	Combined DOCK8 and CLEC7A mutations causing immunodeficiency in 3 brothers with diarrhea, eczema, and infections. <i>Journal of Allergy and Clinical Immunology</i> , <b>2013</b> , 131, 594-7.e1-3	11.5	19
58	IL-21 signalling via STAT3 primes human naive B cells to respond to IL-2 to enhance their differentiation into plasmablasts. <i>Blood</i> , <b>2013</b> , 122, 3940-50	2.2	84
57	Human IL2RA null mutation mediates immunodeficiency with lymphoproliferation and autoimmunity. <i>Clinical Immunology</i> , <b>2013</b> , 146, 248-61	9	141
56	A novel function for FOXP3 in humans: intrinsic regulation of conventional T cells. <i>Blood</i> , <b>2013</b> , 121, 12	6 <u>5-7</u> 5	55
55	Coexpression of CD49b and LAG-3 identifies human and mouse T regulatory type 1 cells. <i>Nature Medicine</i> , <b>2013</b> , 19, 739-46	50.5	525
54	CD4+ T cells from IPEX patients convert into functional and stable regulatory T cells by FOXP3 gene transfer. <i>Science Translational Medicine</i> , <b>2013</b> , 5, 215ra174	17.5	89
53	Immunodeficiency with autoimmunity: beyond the paradox. Frontiers in Immunology, 2013, 4, 77	8.4	9
52	Accumulation of peripheral autoreactive B cells in the absence of functional human regulatory T cells. <i>Blood</i> , <b>2013</b> , 121, 1595-603	2.2	118

## (2008-2013)

51	Autoantibodies to harmonin and villin are diagnostic markers in children with IPEX syndrome. <i>PLoS ONE</i> , <b>2013</b> , 8, e78664	3.7	50
50	Demethylation analysis of the FOXP3 locus shows quantitative defects of regulatory T cells in IPEX-like syndrome. <i>Journal of Autoimmunity</i> , <b>2012</b> , 38, 49-58	15.5	55
49	Gene therapy for primary immunodeficiencies: Part 2. Current Opinion in Immunology, 2012, 24, 585-91	7.8	51
48	Immune dysregulation, polyendocrinopathy, enteropathy, x-linked syndrome: a paradigm of immunodeficiency with autoimmunity. <i>Frontiers in Immunology</i> , <b>2012</b> , 3, 211	8.4	228
47	Forkhead box protein 3 (FOXP3) mutations lead to increased TH17 cell numbers and regulatory T-cell instability. <i>Journal of Allergy and Clinical Immunology</i> , <b>2011</b> , 128, 1376-1379.e1	11.5	47
46	Clinical tolerance in allogeneic hematopoietic stem cell transplantation. <i>Immunological Reviews</i> , <b>2011</b> , 241, 145-63	11.3	60
45	Clinical heterogeneity and diagnostic delay of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. <i>Clinical Immunology</i> , <b>2011</b> , 139, 6-11	9	43
44	Functional type 1 regulatory T cells develop regardless of FOXP3 mutations in patients with IPEX syndrome. <i>European Journal of Immunology</i> , <b>2011</b> , 41, 1120-31	6.1	59
43	Killing of myeloid APCs via HLA class I, CD2 and CD226 defines a novel mechanism of suppression by human Tr1 cells. <i>European Journal of Immunology</i> , <b>2011</b> , 41, 1652-62	6.1	97
42	Methods for in vitro generation of human type 1 regulatory T cells. <i>Methods in Molecular Biology</i> , <b>2011</b> , 677, 31-46	1.4	27
41	Point mutants of forkhead box P3 that cause immune dysregulation, polyendocrinopathy, enteropathy, X-linked have diverse abilities to reprogram T cells into regulatory T cells. <i>Journal of Allergy and Clinical Immunology</i> , <b>2010</b> , 126, 1242-51	11.5	41
40	Molecular and functional characterization of allogantigen-specific anergic T cells suitable for cell therapy. <i>Haematologica</i> , <b>2010</b> , 95, 2134-43	6.6	51
39	Regulated and multiple miRNA and siRNA delivery into primary cells by a lentiviral platform. <i>Molecular Therapy</i> , <b>2009</b> , 17, 1039-52	11.7	74
38	Type 1 regulatory T cells are associated with persistent split erythroid/lymphoid chimerism after allogeneic hematopoietic stem cell transplantation for thalassemia. <i>Haematologica</i> , <b>2009</b> , 94, 1415-26	6.6	53
37	Selective engraftment of donor CD4+25high FOXP3-positive T cells in IPEX syndrome after nonmyeloablative hematopoietic stem cell transplantation. <i>Blood</i> , <b>2009</b> , 113, 5689-91	2.2	65
36	Wild-type FOXP3 is selectively active in CD4+CD25(hi) regulatory T cells of healthy female carriers of different FOXP3 mutations. <i>Blood</i> , <b>2009</b> , 114, 4138-41	2.2	37
35	Interleukin-10 Anergized Donor T Cell Infusion Improves Immune Reconstitution without Severe Graft-Versus-Host-Disease After Haploidentical Hematopoietic Stem Cell Transplantation <i>Blood</i> , <b>2009</b> , 114, 45-45	2.2	11
34	Clinical improvement and normalized Th1 cytokine profile in early and long-term interferon-alpha treatment in a suspected case of hyper-IgE syndrome. <i>Pediatric Allergy and Immunology</i> , <b>2008</b> , 19, 564-8	3 <sup>4.2</sup>	4

33	Clinical and molecular profile of a new series of patients with immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: inconsistent correlation between forkhead box protein 3 expression and disease severity. <i>Journal of Allergy and Clinical Immunology</i> , <b>2008</b> , 122, 110	11.5 <b>)5-111</b>	
32	STAT5-signaling cytokines regulate the expression of FOXP3 in CD4+CD25+ regulatory T cells and CD4+CD25- effector T cells. <i>International Immunology</i> , <b>2008</b> , 20, 421-31	4.9	142
31	Generation of potent and stable human CD4+ T regulatory cells by activation-independent expression of FOXP3. <i>Molecular Therapy</i> , <b>2008</b> , 16, 194-202	11.7	173
30	CD4+ T-regulatory cells: toward therapy for human diseases. <i>Immunological Reviews</i> , <b>2008</b> , 223, 391-421	111.3	194
29	Role of regulatory T cells and FOXP3 in human diseases. <i>Journal of Allergy and Clinical Immunology</i> , <b>2007</b> , 120, 227-35; quiz 236-7	11.5	194
28	Immunological lessons learnt from patients transplanted with fully mismatched stem cells. <i>Immunologic Research</i> , <b>2007</b> , 38, 201-9	4.3	6
27	Activation-induced FOXP3 in human T effector cells does not suppress proliferation or cytokine production. <i>International Immunology</i> , <b>2007</b> , 19, 345-54	4.9	684
26	Tr1 cells: from discovery to their clinical application. <i>Seminars in Immunology</i> , <b>2006</b> , 18, 120-7	10.7	225
25	Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. <i>Immunological Reviews</i> , <b>2006</b> , 212, 28-50	11.3	966
24	Defective regulatory and effector T cell functions in patients with FOXP3 mutations. <i>Journal of Clinical Investigation</i> , <b>2006</b> , 116, 1713-22	15.9	383
23	Utilizing regulatory T cells to control alloreactivity. <i>Cytotherapy</i> , <b>2005</b> , 7, 158-65	4.8	7
22	Induction of transplantation tolerance in humans using fetal cell transplants. <i>Transplantation Proceedings</i> , <b>2005</b> , 37, 65-6	1.1	13
21	Regulatory T cells: prospective for clinical application in hematopoietic stem cell transplantation. <i>Current Opinion in Hematology</i> , <b>2005</b> , 12, 451-6	3.3	17
20	CD4+ regulatory T cells: mechanisms of induction and effector function. <i>Autoimmunity Reviews</i> , <b>2005</b> , 4, 491-6	13.6	140
19	An anti-CD45RO/RB monoclonal antibody modulates T cell responses via induction of apoptosis and generation of regulatory T cells. <i>Journal of Experimental Medicine</i> , <b>2005</b> , 201, 1293-305	16.6	58
18	The role of 2 FOXP3 isoforms in the generation of human CD4+ Tregs. <i>Journal of Clinical Investigation</i> , <b>2005</b> , 115, 3276-84	15.9	334
17	Reappraisal of in utero stem cell transplantation based on long-term results. <i>Fetal Diagnosis and Therapy</i> , <b>2004</b> , 19, 305-12	2.4	33
16	Growth and expansion of human T regulatory type 1 cells are independent from TCR activation but require exogenous cytokines. <i>European Journal of Immunology</i> , <b>2002</b> , 32, 2237-45	6.1	162

#### LIST OF PUBLICATIONS

15	The role of IL-10 and TGF-beta in the differentiation and effector function of T regulatory cells. <i>International Archives of Allergy and Immunology</i> , <b>2002</b> , 129, 263-76	3.7	306
14	Type 1 T regulatory cells. <i>Immunological Reviews</i> , <b>2001</b> , 182, 68-79	11.3	684
13	T-cell subsets and their cytokine profiles in transplantation and tolerance. <i>Annals of the New York Academy of Sciences</i> , <b>1995</b> , 770, 141-8	6.5	4
12	High levels of interleukin 10 production in vivo are associated with tolerance in SCID patients transplanted with HLA mismatched hematopoietic stem cells. <i>Journal of Experimental Medicine</i> , <b>1994</b> , 179, 493-502	16.6	353
11	Human Ig production and isotype switching in severe combined immunodeficient-human mice. <i>Journal of Immunology</i> , <b>1993</b> , 151, 128-37	5.3	23
10	Chimerism and tolerance to host and donor in severe combined immunodeficiencies transplanted with fetal liver stem cells. <i>Journal of Clinical Investigation</i> , <b>1993</b> , 91, 1067-78	15.9	31
9	Expression of conformationally constrained adhesion peptide in an antibody CDR loop and inhibition of natural killer cell cytotoxic activity by an antibody antigenized with the RGD motif. <i>EMBO Journal</i> , <b>1993</b> , 12, 4375-84	13	7
8	Human hematopoietic cells and thymic epithelial cells induce tolerance via different mechanisms in the SCID-hu mouse thymus. <i>Journal of Experimental Medicine</i> , <b>1992</b> , 175, 1033-43	16.6	60
7	Interleukin 10 inhibits allogeneic proliferative and cytotoxic T cell responses generated in primary mixed lymphocyte cultures. <i>International Immunology</i> , <b>1992</b> , 4, 1389-97	4.9	125
6	A SCID patient reconstituted with HLA-incompatible fetal stem cells as a model for studying transplantation tolerance. <i>Nouvelle Revue Fran</i> aise <i>Dthlinatologie</i> , <b>1991</b> , 17, 391-402		8
5	Natural killer cell clones can efficiently process and present protein antigens. <i>Journal of Immunology</i> , <b>1991</b> , 147, 781-7	5.3	54
4	Host-reactive CD4+ and CD8+ T cell clones isolated from a human chimera produce IL-5, IL-2, IFN-gamma and granulocyte/macrophage-colony-stimulating factor but not IL-4. <i>Journal of Immunology</i> , <b>1990</b> , 144, 902-8	5.3	79
3	Interleukin-2 production and interleukin-2 receptor expression in children with newly diagnosed diabetes. <i>Clinical Immunology and Immunopathology</i> , <b>1988</b> , 49, 53-62		23
2	Antigen recognition by MHC-incompatible cells of a human mismatched chimera. <i>Journal of Experimental Medicine</i> , <b>1988</b> , 168, 2139-52	16.6	62

146 Alloantigen-specific Tr1 cells designed to prevent GvHD have a distinct molecular identity and suppress through CTLA-4 and PD-1